Century Therapeutics Eyes IND Filing for Diabetes Therapy, Holds $217M Runway
Century Therapeutics advanced its CNTY-813 type 1 diabetes iPSC-derived islet therapy through IND-enabling studies, aiming to file an IND in Q4 2026 with initial clinical data in H2 2027. Cash, cash equivalents and marketable securities totaled $217M on March 31, 2026, providing runway into Q1 2029.
1. iPSC-Derived Islet Therapy Progress
Century advanced CNTY-813 through key IND-enabling activities in Q1 2026, including nonclinical development, GMP master cell bank manufacturing and FDA interactions. The company plans to submit an IND in Q4 2026 and expects initial clinical data in H2 2027, with preclinical results to be presented at the ADA Scientific Sessions on June 8, 2026.
2. CAR-iT Cell Therapy Advancement
The CD19-targeted CNTY-308 program is progressing through IND-enabling studies, leveraging Allo-Evasion™ 5.0 engineering for allogeneic CAR-T cells. Century remains on track to initiate clinical testing for CNTY-308 in 2026, based on preclinical data showing target-specific proliferation, cytokine secretion and durable persistence.
3. Strong Cash Position and Q1 Financials
Century held $217.0 million in cash, cash equivalents and marketable securities as of March 31, 2026, extending its operating runway into Q1 2029 after Q1 net cash use of $25.3 million. R&D expenses decreased to $17.1 million from $26.6 million year-over-year, G&A expenses fell to $6.6 million from $8.4 million, and net loss was $21.6 million versus a $76.6 million income in Q1 2025.